Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.63, No.5, p.774-778,2016 |
||
Title: Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model | ||
Author: M. KLANOVA, T. SOUKUP, J. MOLINSKY, L. LATECKOVA, P. VOCKOVA, M. ALAM, J. ZIVNY, M. TRNENY, P. KLENER | ||
Abstract: Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin lymphoma with adverse prognosis. It was demonstrated that alternation of CHOP and DHAP chemotherapy improved outcome of mantle cell lymphoma patients. However, which components of DHAP, cisplatin, cytarabine, or both, were responsible for the improved outcome remained unclear. To answer this question, antitumor efficacies of equally toxic doses of cytarabine, cisplatin, and three different combinations were compared in vivo using mouse xenograft models of mantle cell lymphoma. We demonstrated that cisplatin, alone or with cytarabine, is significantly superior to single-agent cytarabine in both eliminating lymphoma cells and suppressing their proliferation rate. |
||
Keywords: mantle cell lymphoma (MCL), cisplatin, high-dose cytarabin, DHAP | ||
Published online: 09-Sep-2016 | ||
Year: 2016, Volume: 63, Issue: 5 | Page From: 774, Page To: 778 | |
doi:10.4149/neo_2016_515 |
||
|
download file |
|